Loading up on growth stocks while they're at bargain prices can lead to some great long-term returns for investors. And with many of these stocks falling in recent weeks, there are plenty of good deals available right now. Among the cheapest stocks to consider include Bristol Myers Squibb ( NYSE:BMY ) and Dell Technologies ( NYSE:DELL ) . Both are trading at low earnings multiples and still possess many growth opportunities, so now could be an optimal time to add these safe investments to your portfolio. Image source: Getty Images. 1. Bristol Myers Squibb Although Bristol Myers pays an incredibly attractive 3.6% dividend yield, which is well above the S&P 500 average of 1.3%, you shouldn't overlook the growth potential here. Acquisitions have helped the company expand its top line (sales of $42.5 billion in 2020 were more than double the $20.8 billion Bristol Myers reported just three years earlier) and its portfolio of drugs. In 2019, Bristol Myers … [Read more...] about 2 Absurdly Cheap Growth Stocks to Buy in December
What happened Shares of Eli Lilly ( NYSE:LLY ) were jumping 8.3% as of 11:48 a.m. ET on Wednesday. The big gain came after the drugmaker provided an update for investors. Lilly announced that it has initiated a rolling submission to the Food and Drug Administration for pirtobrutinib in treating mantle cell lymphoma. The company said that it's planning new phase 3 clinical studies evaluating tirzepatide in obesity outcomes, sleep apnea, and kidney disease. It also released new biomarker data showing positive efficacy for donanemab in treating Alzheimer's disease. Investors were most excited, though, about Lilly's updated guidance. The company looks for full-year 2021 revenue to be between $28 billion and $28.3 billion, with adjusted earnings per share (EPS) between $8.15 and $8.20. Both ranges are well above consensus estimates. Lilly also projects 2022 revenue will be between $27.8 billion and $28.3 billion with adjusted (EPS) between $8.50 and $8.65. This outlook is also … [Read more...] about Why Eli Lilly Stock Is Jumping Today
There's a common expression in the investing community, which goes as follows: "It's a market of stocks, not a stock market." This essentially means that even with the financial markets at or near all-time highs as they are now, not all stocks have fared well. Pharma stock Amgen ( NASDAQ:AMGN ) is a perfect example. At its current share price of $204, the stock is just a touch above its 52-week low and a whopping 26% below its 52-week high. Let's look at whether you should interpret this recent poor stock performance as a buying opportunity or a sign to steer clear of Amgen. Image source: Getty Images. A solid third-quarter performance Amgen reported $6.7 billion in revenue during the third quarter, which equates to a 4.4% growth rate against the year-ago period. What led to Amgen's respectable performance? Given Amgen's diversified portfolio of more than two dozen drugs, there were quite a few moving parts affecting growth in the quarter. Legacy medications such … [Read more...] about Should You Buy This Giant Biotech Stock?
Dividends can be a great source of passive income, and they can also help supercharge your portfolio's growth if you take advantage of automatic dividend reinvestment. In other words, no matter your investment style, dividend-paying stocks can help you reach your goals -- and one that looks like a particularly excellent option right now is Amgen ( NASDAQ:AMGN ) . AMGN data by YCharts Recent drug approvals will help boost top-line growth At first glance, Amgen's business doesn't look particularly strong. In the third quarter, its total revenue came in at $6.7 billion, representing a meager 4% year-over-year increase. One reason for that unimpressive growth is that some of its key products are now out of patent protection and facing off against biosimilars in the market. For instance, sales of Neulasta, which stimulates the production of infection-fighting white blood cells in cancer patients, decreased by 25% year over year in the third quarter to $415 million. … [Read more...] about 1 Top Dividend Stock to Buy and Hold in 2022 and Beyond
Investors have been taken on quite the ride over the past 21 months. They've navigated their way through the quickest decline of at least 30% in the history of the benchmark S&P 500 , and have reveled in what's become the strongest bounce back from a bear-market bottom on record. But in spite of the S&P 500 hitting more than five dozen all-time closing highs in 2021, bargains still abound for opportunistic investors. Even better, with most online brokerages doing away with minimum deposit requirements and trading commissions, any amount of money can be put to work and used to further your trek to financial independence -- even $100. If you have $100 that's ready to be invested in the market, which won't be needed for bills or emergencies, the following three no-brainer stocks would make for perfect buys right now. Image source: Getty Images. Western Digital Investors often think of growth stocks and value stocks as existing in their own realms. In other … [Read more...] about 3 No-Brainer Stocks to Invest $100 In Right Now
Since the stock market bottomed out in March 2020, investors have enjoyed historic gains. It took less than 17 months for the broad-based S&P 500 to double from its bear market low. Furthermore, the widely followed index came close to tripling its long-term average annual return in 2021. Despite this incredible outperformance, amazing deals remain. Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. If you have cash ready to invest and are willing to let time be your ally, the following four stocks all have the tools to turn $100,000 into $1 million by 2030. Image source: Getty Images. Teladoc Health There's no sugarcoating it: telehealth giant Teladoc Health ( NYSE:TDOC ) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its … [Read more...] about 4 Stocks That Can Turn $100,000 Into $1 Million by 2030